ViroPharma Inc. (VPHM)
-NasdaqGS 25.88 
0.26(1.01%) May 17, 4:00PM EDT|After Hours
:
25.88 0.00 (0.00%) May 17, 4:32PM EDT
| Prev Close: | 25.62 |
|---|
| Open: | 25.71 |
|---|
| Bid: | 25.40 x 200 |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 33.33 |
|---|
| Beta: | 1.43 |
|---|
| Next Earnings Date: | 5-Aug-13 |
|---|
| Day's Range: | 25.42 - 25.88 |
|---|
| 52wk Range: | 19.22 - 31.36 |
|---|
| Volume: | 326,222 |
|---|
| Avg Vol (3m): | 537,151 |
|---|
| Market Cap: | 1.69B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.20 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Halozyme rises on pancreatic cancer drug studyAP(Thu, May 16)
- Halozyme rises on prostate cancer drug studyAP(Thu, May 16)
- ViroPharma Proudly Supports HAE Day :-) 2013PR Newswire(Thu, May 16)
- Viropharma's CEO Presents at Bank of America Merrill Lynch Health Care Conference (Transcript)at Seeking Alpha(Wed, May 15)
- ViroPharma (VPHM) Shares Cross Above 200 DMAat TheStreet(Mon, May 13)
- ViroPharma To Participate In Two May Healthcare Investor ConferencesPR Newswire(Thu, May 9)
- VIROPHARMA INC FinancialsEDGAR Online Financials(Tue, May 7)
- Biota Pharmaceuticals Announces Changes to Its Board of DirectorsGlobeNewswire(Mon, May 6)
- Despite Poor Quarter, ViroPharma's Commercial And Pipeline Progress Continueat Seeking Alpha(Fri, May 3)
- ViroPharma Reports Loss in 1QZacks(Thu, May 2)
- The Zacks Analyst Blog Highlights: AT&T, Optimer Pharmaceuticals, ViroPharma, Astellas Pharma and IncyteZacks(Thu, May 2)
- Optimer's Dificid Cleared Down UnderZacks(Wed, May 1)
- ViroPharma Management Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Wed, May 1)
- ViroPharma's Maribavir: Rising Like Phoenixat Seeking Alpha(Wed, May 1)
- Positive News in the Oncology Space Regarding Myeloma and Melanoma Drugs: Expert Analyst Boris Peaker Discusses Recent Successes for Biotechnology CompaniesWall Street Transcript(Wed, May 1)
Key Statistics
| Forward P/E (1 yr): | 33.61 |
|---|
| P/S (ttm): | 4.19 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.68 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.03 |
|---|
| Mean Recommendation*: | 1.8 |
|---|
| PEG Ratio (5 yr expected): | -4.74 |
|---|
Business Summary
ViroPharma Incorporated, a biotechnology company, develops and commercializes therapeutic products that address serious diseases in the United States and internationally.
View More